- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.02. | Flagship's AI-focused Generate Biomedicines files IPO | ||
| 05.02. | Amgen baulks at FDA request to withdraw Tavneos | ||
| 05.02. | Grail multi-cancer test taps into Hims & Hers network | ||
| 05.02. | Abbott's wireless heart failure sensor cleared for NHS use | ||
| 05.02. | Eikon, Veradermics close IPOs, as Salspera joins queue | ||
| 04.02. | Lilly says 2026 looks good, as sales rocket in Q4 | ||
| 04.02. | GSK delivers in new CEO Miels' first financial update | ||
| 04.02. | Novo Nordisk slumps on tougher 2026 financial outlook | ||
| 04.02. | Patent losses hit Novartis hard, but CEO has a plan | ||
| 04.02. | Fears US drug pricing deal will weigh heavy on the NHS | ||
| 03.02. | GSK departs Wave's AATD programme | ||
| 03.02. | FDA knocks back AstraZeneca's self-injected lupus drug | ||
| 03.02. | UK will cover transport costs for children with cancer | ||
| 03.02. | Novo Nordisk's CagriSema tops Ozempic in diabetes trial | ||
| 03.02. | GSK kicks out of Wave's AATD programme | ||
| 02.02. | UK body raps Sanofi for disparaging Pfizer's RSV jab | ||
| 02.02. | FDA knocks back Pharming's bid for wider Joenja use | ||
| 02.02. | Mixed data mars Sanofi's venglustat programme | ||
| 02.02. | Mixed data mar Sanofi's venglustat programme | ||
| 02.02. | FDA launches pilot programme to boost US manufacturing | ||
| 02.02. | UCB bags first EU approval for rare genetic disease TK2d | ||
| 02.02. | Lilly names Pennsylvania site for its latest US facility | ||
| 30.01. | EMA looks into 'data integrity' issue with Amgen's Tavneos | ||
| 30.01. | FDA starts review of Summit's VEGFxPD-1 bispecific | ||
| 30.01. | Three more biotechs price their Nasdaq IPOs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.